UNSPSC 51361935: Methitural sodium

This classification denotes a barbiturate with the molecular formula C12H19N2O2S2.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 054NQ722GD, chemically known as 4,6(1h,5h)-pyrimidinedione, dihydro-5-(1-methylbutyl)-5-(2-(methylthio)ethyl)-2-thioxo-, sodium salt (1:1), but more generally known as methitural sodium, which bears US NIH Compound Identifier 3034668. European Medicines Agency schedules methitural sodium or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08851MIG.

Most nations, for tariff purposes, schedule methitural sodium under HS 29335400. SMILES: CCCC(C)C1(C(=O)NC(=S)[N-]C1=O)CCSC.[NA+].

UNSPSC 51361935 Methitural sodium, a Commodity code, covers pharmaceutical products procured by state and local health agencies, though recent state and local opportunities tagged under this code do not focus on methitural sodium specifically. Instead, the recent solicitations show state and local governments buying naloxone and drug deactivation systems for harm-reduction initiatives, direct-to-manufacturer prescription fulfillment programs through state HHS commissions, and generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing alliances. The issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and multistate cooperative purchasing organizations (Minnesota Multistate Cooperative Purchasing Alliance administering on behalf of member states and participating jurisdictions including Oregon). These purchases support community health programs, pharmacy benefit management for state employees and Medicaid populations, and bulk pharmaceutical distribution to state and local facilities.

Geographic activity spans Florida, Texas, Minnesota, and Oregon based on recent solicitations. Seminole County, Florida posted IFB 60459723LAS on June 30, 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a July 26, 2023 response deadline. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026 to explore direct-to-manufacturer prescription contracting models outside traditional pharmacy benefit manager and wholesaler arrangements. The Minnesota Department of Administration's Office of State Procurement, administering the MMCAP cooperative, released RFP S1070000015802 on January 20, 2026 for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 response deadline, requiring vendor pricing for identified products through three authorized wholesalers and compliance with FDA requirements, cGMP certification, and the Drug Supply Chain Security Act.